Medical Devices industry cross border deals total $4.6bn globally in July 2021

Total medical devices industry cross border deals worth $4.6bn were announced globally for July 2021, with the $1.21bn private equity deal with Lifebrain being the sector’s biggest investment, according to GlobalData’s deals database.

The value marked a decrease of 87.9% over the previous month of $38bn and a drop of 28.4% when compared with the last 12-month average of $6.41bn.

In terms of number of cross border deals, the sector saw a rise of 13.95% with 49 deals in July 2021 when compared to the last 12-month average of 43 deals.

In value terms, Europe led the activity with cross border deals worth $2.69bn in July 2021.

medical devices industry cross border deals in July 2021: Top deals

The top five cross border deals accounted for 69.7% of the overall value during July 2021.

The combined value of the top five cross border deals stood at $3.2bn, against the overall value of $4.6bn recorded for the month.

The top five medical devices industry cross border deals of July 2021 tracked by GlobalData were:

1) Lifebrain $1.21bn private equity deal with EQT Partners

2) The $1.17bn acquisition of Vectura Group by Philip Morris International

3) Simbionix USA $305m acquisition deal with Surgical Science Sweden

4) The $250m private equity of Certara USA by Mubadala Investment

5) Imperative Care $260m venture financing deal with Ally Bridge Group,AMED Ventures GP,Ascension Health Ventures,Bain Capital Life Sciences,D1 Capital Partners,Delos Capital,HealthCor Management,Innovatus Capital Partners and Rock Springs Capital Management